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Abstract
Aims This bioequivalence study was conducted to assess
the bioequivalence of two formulations, test and reference,
of pregabalin 300 mg hard capsules, under fasting
conditions.
Methods This was a single-center, randomized, single-
dose, open-label, laboratory-blinded, two-way crossover
study, with a minimum washout period of 7 days. Plasma
samples were collected prior to and up to 36 h after dosing.
Pregabalin plasma concentrations were determined, using a
validated method, by reversed phase high performance
liquid chromatography coupled to a tandem mass spec-
trometry detector (LC–MS–MS). Pharmacokinetic metrics
used for bioequivalence assessment were the AUC(0–t)
(area under the plasma concentration–time curve from time
zero to time of last observed non-zero plasma concentra-
tion) and the Cmax (maximum observed plasma concen-
tration). These parameters were determined from the
pregabalin plasma concentration data using noncompart-
mental analysis.
Results Forty healthy subjects, age ranging from 18 to
43 years old, were enrolled and randomized, of whom 39
completed the study. The ratio of geometric least square
means for Cmax was 99.29 % (90 % confidence interval
[CI] 93.29–105.67). The ratio of geometric least square
means for AUC(0–t) was 101.54 % (90 % CI
100.13–102.98). The 90 % CIs were within the predefined
range (80.00–125.00).
Conclusions Bioequivalence between test and reference
formulations, under fasting conditions, was concluded both
in terms of rate and extent of absorption.
1 Introduction
Pregabalin, the (S)-3-(aminomethyl)-5-methylhexanoic
acid (ATC N03AX16; CAS 148553-50-8), selectively
binds with high affinity to the a2-d subunit of voltage-gated
calcium channels, widely distributed throughout the central
and peripheral nervous systems. This modulates calcium
influx in presynaptic nerve terminals to reduce excessive
release of several excitatory neurotransmitters. Pregabalin
is structurally related to the naturally occurring amino acids
L-leucine and c-aminobutyric acid (GABA) [1, 2]. Prega-
balin is indicated for the treatment of peripheral and central
neuropathic pain in adults, adjunctive therapy in adults
with partial seizures with or without secondary general-
ization, and treatment of generalized anxiety disorder
(GAD) in adults. The dose range is 150–600 mg per day
given in either two or three divided doses [1].
Pregabalin is absorbed rapidly (peak plasma concen-
trations occur within 1.5 h) after oral administration and
exposure to single (25–300 mg/day) or multiple dosages
(75–900 mg/day) is dose proportional. The oral bioavail-
ability of pregabalin is high (C90 %) and independent of
dose. The rate of pregabalin absorption is decreased when
given with food, resulting in a decrease in Cmax (maximum
observed plasma concentration) of approximately 25–30 %
and an increase in tmax (time to maximum concentration) to
approximately 3 h. However, administration of pregabalin
with food has no clinically relevant effect on the total
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absorption of pregabalin. Therefore, pregabalin can be
taken with or without food. Pregabalin does not bind to
plasma proteins. The apparent volume of distribution fol-
lowing oral administration is approximately 0.5 L/kg.
Metabolism of pregabalin is negligible with most of the
drug excreted unchanged in the urine with a mean
elimination half-life of 6.3 h in subjects with normal renal
function. Pregabalin plasma clearance and renal clearance
are directly proportional to creatinine clearance [1–4].
Pregabalin pharmacokinetics is linear over the recom-
mended daily dose range [1–3]. According to the European
guideline, two medicinal products containing the same
active substance are considered bioequivalent if they are
pharmaceutically equivalent or pharmaceutical alternatives
and their bioavailabilities (rate and extent) after adminis-
tration in the same molar dose lie within acceptable pre-
defined limits. These limits are set to ensure comparable
in vivo performance; that is, similarity in terms of safety
and efficacy [5].
This study aimed to compare the rate and extent of
absorption of a test formulation of pregabalin 300 mg and
those of the European reference medicinal product (Lyri-
ca), administered as a 1 9 300 mg capsule under fasted
conditions, a surrogate for therapeutic equivalence.
2 Volunteers and Methods
2.1 Study Protocol
An independent ethics committee approved the clinical
study protocol and a letter of no-objection was obtained
from the Canadian authorities on 5 May, 2011. The study
was performed in accordance with the Helsinki Declaration
[6] and Good Clinical Practice Guideline [7] and informed
consent was obtained from participants prior to study
commencement. The clinical part of the study was con-
ducted at Algorithme Pharma Clinical Research Facility
(Mount-Royal, QC, Canada) and the bioanalytical part at
Anapharm Europe, SL facility (Barcelona, Spain). Phar-
macokinetic and statistical analyses were also performed
by Algorithme Pharma Inc. (Laval, QC, Canada).
2.2 Volunteers
Subjects were judged eligible for enrollment if they were in
compliance with all the inclusion and exclusion criteria
described in the protocol. Subjects included in this study
were male, healthy, adult non-smokers or ex-smokers, aged
C18 years and B45 years with body mass indices (BMI)
C22.0 and \30.0 kg/m2. Clinically significant diseases
were not captured in the medical history, and no evidence
of clinically significant findings on physical examination
and/or clinical laboratory evaluations (hematology, bio-
chemistry, ECG and urinalysis) was found. The following
procedures were performed at screening: medical history,
demographic data (including sex, age, race, body weight
[kg], height [cm], and BMI [kg/m2]), vital signs measure-
ments, 12-lead electrocardiogram (ECG), physical ex-
amination, urine ethanol and drugs of abuse screen, and
clinical laboratory tests (hematology, biochemistry, uri-
nalysis, human immunodeficiency virus [HIV], hepatitis C
[HCV] antibodies, and hepatitis B surface antigen
[HBsAg]).
The sample size was estimated from Algorithme’s in-
house data on intra-subject coefficients of variation
(ISCVs) for AUC (area under the plasma concentration
curve) and Cmax. Considering this information and an ex-
pected ratio of AUC and Cmax within 0.90 and 1.11, the
study was expected to have a power of at least 80 % to
show bioequivalence. Forty healthy male subjects were
randomly assigned to test formulation or reference for-
mulation in accordance with the randomization scheme
previously generated using computerized software; 39/40
subjects completed the crossover design and were included
in the pharmacokinetic and statistical analysis. The safety
population included 40 subjects.
2.3 Drug Products
Pregabalin 300 mg hard capsule, manufactured by West
Pharma, S.A. for Tecnimede, Sociedade Te´cnico-Medici-
nal S.A. (batch no. 11753, expiry date 30/09/2012) was
compared with the Portuguese reference product, Lyrica
300 mg hard capsule (batch no: 0332128P; expiry date
11/2011), manufactured by Pfizer GmbH (Germany) and
acquired from a local pharmacy.
2.4 Study Design
The aim of this study was to compare the rate and extent of
absorption of the test product of pregabalin 300 mg hard
capsule (manufactured by West Pharma, S.A. for Tecni-
mede, Sociedade Te´cnico-Medicinal S.A., Sintra, Portugal)
with the reference product, Lyrica 300 mg hard capsule
(manufactured by Pfizer GmbH, Germany), administered
as a 1 9 300 mg capsule, under fasting conditions. This
was a single-center, randomized, single-dose, laboratory-
blinded, open-label, two-period, two-sequence, crossover
bioequivalence study in healthy volunteers.
Subjects were assigned to one of two treatment se-
quences. No food was allowed from at least 10 h before
dosing until at least 4 h after dosing, after which a stan-
dardized lunch was served. A supper and a light snack were
also served at appropriate times thereafter, but not before
9 h after dosing. With the exception of the 240 mL of
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water administered at the time of dosing, fluids were not
permitted from 1 h before dosing to 1 h after dosing; water
was permitted ad libitum at all other times.
The treatment periods were separated by a washout
period of 7 days.
2.5 Randomization and Blinding
The order of investigational product administration was
sequentially assigned from a computer-generated random-
ization scheme. The randomization scheme was kept
unavailable to the bioanalytical division until completion
of both the clinical and analytical phases.
2.6 Drug Analysis
Subjects were confined to the Algorithme Pharma Clinical
Research Facility from at least 10 h prior to drug adminis-
tration until after the 36-h post-dose blood draw, in each
period. Blood samples were collected in pre-cooled K2
EDTA (dipotassium ethylene diamine tetra-acetic acid)
Vacutainers, prior to study drug administration and 0.25,
0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 3.00, 4.00,
6.00, 9.00, 12.0, 16.0, 24.0 and 36.0 h post-dose in each
period. Within 110 min after blood collection, samples were
centrifuged at a temperature of 4 C nominal and at ap-
proximately 19009g for 10 min. The plasma obtained was
separated into duplicate polypropylene culture tubes, when
feasible. The tubes were labeled with a code number that did
not reveal treatment identity. The samples were frozen in an
upright position and retained in the clinic’s freezers at a
temperature of -20 C nominal until sent on dry ice to the
analytical facility for assay. The experimental samples were
assayed for pregabalin using a validated chromatographic
method with mass spectrometry detection (LC–MS/MS).
The sample pretreatment required one-step preparation with
the addition of methanol in order to promote protein pre-
cipitation; 900 lL of internal standard (IS) solution in
methanol was added to 100 lL of plasma and vortexed for
60 s; 200 lL of the clear supernatant was transferred into
vials and a 10 lL aliquot of each sample was injected into
the LC–MS/MS system. Chromatographic separation was
achieved through an Agilent Zorbax SB-C18 (50 9 4.6 mm,
3.5 lm) at room temperature. For the mobile phase, a
mixture of methanol: 1 mM ammonium acetate (75:25, v/v)
and 0.1 % of formic acid was used at a flow rate of 1
mL/min. Quantification was performed using a selected
reaction monitoring (SRM) of the transitions m/z
160.2[ 142.3 for pregabalin and m/z 163.8[ 146.3 for IS.
The LC–MS/MS method for the quantification of pre-
gabalin was specific and linear in the range of
30–15,000 ng/mL. A calibration curve was analyzed for
each set of samples. The method showed good linearity
over the studied range (r C 0.9997). The between-run ac-
curacy ranged from 100.34 to 101.24 % and precision
(expressed as the CV %) ranged between 1.66 and 5.35 %.
The within-run accuracy ranged from 99.21 to 107.28 %
and precision ranged from 1.22 to 6.25 %.
Analyses of drug concentrations were performed ac-
cording to OECD (Organisation for Economic Co-op-
eration and Development) good laboratory practice (GLP)
standards and validation results were in accordance with
the international requirements for bioanalytical methods,
allowing the use of the method in the present bioe-
quivalence study.
2.7 Pharmacokinetic Analysis
Pharmacokinetic analyses were performed using Kinetic
software (version 9.01; Algorithme Pharma Inc., Laval,
Canada).
Individual and mean pregabalin plasma concentrations
were plotted over the sampling period using untransformed
and ln-transformed data. Only subjects with concentration
data for both test drug product and reference drug product
were included in the pharmacokinetic analysis. Drop-out
subjects were not to be replaced. If a pre-dose concentra-
tion of pregabalin was detected, the subject’s data could be
included in the pharmacokinetic and statistical analysis,
without adjustment, if it was B5 % of the Cmax value of the
corresponding period. If it was[5 % of the Cmax value, the
subject was to be dropped from all pharmacokinetic and
statistical evaluations of pregabalin.
The following pharmacokinetic metrics were to be cal-
culated: maximum observed plasma concentration (Cmax),
time of maximum measured plasma concentration (tmax),
cumulative area under the plasma concentration time curve
calculated from 0 to time of the last quantifiable concen-
tration (tLQC) using the linear trapezoidal method
(AUC(0–t)), extrapolated area under the plasma concentra-
tion time curve to infinity (AUC(0–?)), apparent elimina-
tion rate constant estimated from a non-linear least-squares
regression model (Kel) and half-life of elimination (tel).
The main absorption and disposition parameters were to
be estimated using a noncompartmental approach with a
log-linear terminal phase assumption. The trapezoidal rule
was to be used to estimate the area under the curve and the
terminal phase was to be estimated by maximizing the
coefficient of determination estimated from the log-linear
regression model. However, they were not to be estimated
for individual concentration–time profiles where the ter-
minal log-linear phase could not be reliably characterized.
The mean, medium, minimal value, standard deviation
and coefficient of variation were to be calculated for
plasma concentrations at each individual time point and for
all pharmacokinetic parameters.
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2.8 Statistical Analysis
Statistical analyses were generated with SAS software
(version 9, SAS Institute Inc., Cary, NC, USA) using the
GLM (general linear model) procedure.
The assessment of bioequivalence was based upon 90 %
confidence intervals for the ratio of the population
geometric means for AUC(0–t) and Cmax obtained after test
and reference drug product dosing. The natural logarithmic
transformation of Cmax, AUC(0–t) and AUC(0–?) were used
for statistical inference. The parameter tmax was analyzed
using a nonparametric approach. The evaluation of fixed
period, sequence and treatment effects were based on the
Wilcoxon’s rank sum test (Mann–Whitney U test).
The other untransformed and ln-transformed pharma-
cokinetic variables were analyzed using an analysis of
variance (ANOVA) model. The fixed factors included in
this model were the subject effect (nested within sequence),
the treatment received, the period at which it was given and
the sequence in which each treatment was being received.
The sequence, period and treatment effects were to be
assessed at the 5 % two-sided level. Furthermore, the 90 %
confidence interval for the exponential of the difference in
least square (LS) means between the test drug product and
the reference drug product was to be calculated for the ln-
transformed parameters (test to reference ratio of geometric
LS means). Bioequivalence assessment was to be based on
the 80.00–125.00 % range.





, where MSE is the mean square
error obtained from the ANOVA model of the ln-trans-
formed parameters. If a pharmacokinetic metric could have
not been determined for one period in a subject, the cor-
responding subject was to be excluded for the particular
statistical comparison.
The intra-subject variation following a single dose of
pregabalin could be as high as 19 % for Cmax and 6 % for
AUC(0–t). Statistically, given that the expected test to refer-
ence ratio of geometric LS means should fall within 90 and
111 %, it was estimated that the lowest number of subjects to
meet the 80.00 to 125.00 % bioequivalence range with a
statistical a priori power of at least 80 % was about 34.
Therefore, the inclusion of 40 subjects was estimated to
be sufficient to also take into account the possibility of
drop-outs, variations around the estimated ISCV, and to
conclude in favor of the hypothesis of bioequivalence with
sufficient statistical power.
2.9 Tolerability Analysis
Adverse events (AEs) were listed and coded using Medical
Dictionary for Regulatory Activities (MedDRA), version
14.0. Adverse events were summarized descriptively in the
safety population, and were tabulated by treatment group,
system organ class (SOC), preferred term (PT), causality,
and severity.
3 Results
3.1 Pharmacokinetic and Statistical Analysis
Forty male healthy volunteers were enrolled and random-
ized. One subject dropped out and 39 completed both pe-
riods of the study. Pharmacokinetic and statistical analysis
included 39 volunteers. The disposition of the subjects is
presented in Fig. 1. The pharmacokinetic metrics were not
adjusted for differences in assayed content of the test and
reference drug product batch. A summary of the pharma-
cokinetic metrics obtained for test drug product and ref-
erence drug product is presented in Table 1.
The mean Cmax were, respectively, 7375.91 and
7420.08 ng/mL for the test and reference. The ratio of
geometric LS means was 99.29 % (90 % confidence in-
terval [CI] 93.29–105.67). The mean AUC(0–t) were, re-
spectively, 54,808.13 and 53,959.26 ngh/mL for test and
reference. The ratio of geometric LS means was 101.54 %
(90 % CI 100.13–102.98). Both ratios of geometric LS
means and 90 % CI were within the prespecified bioe-
quivalence range (80.00–125.00). The mean AUC(0–?)
were, respectively, 56,132.73 and 55,236.37 ngh/mL for
the test and reference. The ratio of geometric LS means
was 101.59 % (90 % CI 100.06–103.14). The median tmax
were 1.03 and 1.25 h for the test and reference, respec-
tively. The mean Kel were 0.1071 and 0.1068 h
-1 for the
test and reference, respectively. Finally, the mean tel were
6.47 and 6.49 h, for the test and the reference, respectively.
The mean of the individual ratio of AUC(0–t) over
AUC(0–?) (AUC(0–t)/AUC(0–?)) were 97.64 and 97.69 %
for the test and reference, respectively. The ISCV was 16.4
and 3.7 % for Cmax and AUC(0–t), respectively.
The mean measured plasma concentration versus time
profile obtained after the administration of the test and
reference is depicted in Fig. 2.
The parameter tmax was analyzed using a non-parametric
approach. The F-value for treatment was 0.10 and the
p value was not significant (p = 0.92115).
3.2 Tolerability Analysis
Thirty-six of the 40 (90 %) subjects included in this study
experienced a total of 158 AEs. Thirty-one (79.5 %) sub-
jects reported 67 AEs, corresponding to five different SOCs
and 13 different PTs, after the single-dose administration of
the test product, and 35 (87.5 %) subjects reported 91 AEs
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(seven different SOCs and 22 different PTs) after the sin-
gle-dose administration of the reference product. The in-
tensity of AEs ranged from mild to severe, and one AE
(dizziness) had no assigned degree of severity. Five severe
AEs (fatigue, headache, somnolence [two occurrences]
following test, and somnolence following reference) were
observed during the study. None of the AEs judged to be
related to the investigational products were unexpected. No
20 subjects allocated to test drug 
product
• 20 received allocated treatment
• 0 did not received allocated treatment
20 subjects allocated to reference drug 
product
• 20 received allocated treatment
• 0 did not received allocated treatment
20 subjects allocated to reference drug 
product
• 20 received allocated treatment
• 0 did not received allocated treatment
20 subjects allocated to test treatment
• 19 received allocated treatment
• 1 did not received allocated treatment
8 subjects excluded
• 4 in stand-by not 
included.
• 4 withdrew the consent. 
48 subjects evaluated for 
eligibility
40 subjects randomized 
40 subjects included in safety analyzis 






Fig. 1 Disposition of subjects.
Test drug product = Sociedade
Te´cnico Medicinal—S.A.,
Portugal, pregabalin
1 9 300 mg hard capsule.
Reference drug
product = Pfizer GmbH,
Germany (Lyrica), pregabalin
1 9 300 mg hard capsule
Table 1 Pharmacokinetic
variables (mean and coefficient
of variation [CV]) for test and
reference drug product
Variable Test drug product Reference drug product
Geometric mean CV (%) Geometric mean CV (%)
Cmax (ng/mL) 7375.91 24.9 7420.08 26.5
tmax (h)
a 1.03 51.8 1.25 42.3
AUC(0–t) (ngh/mL) 54,808.13 12.8 53,959.26 14.0
AUC(0–?) (ngh/mL) 56,132.73 13.4 55,236.37 14.5
AUC(0–t)/(0–?) (%) 97.64 1.2 97.69 1.1
Kel (h
-1) 0.1071 12.7 0.1068 12.6
tel (h) 6.47 12.1 6.49 12.1
AUC(0–?) area under the plasma concentration time curve to infinity, AUC(0–t) area under the plasma
concentration–time curve from time zero to time of last observed non-zero plasma concentration, Cmax
maximum observed plasma concentration, Kel apparent elimination rate constant estimated from a non-
linear least-squares regression model, tel half-life of elimination, tmax time of maximum measured plasma
concentration
a Median is presented for tmax
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serious AEs or deaths were reported during this study. One
(2.5 %) subject took a concomitant medication during the
study. No subject was withdrawn from the study for safety
reasons.
4 Discussion
Pregabalin is indicated for the treatment of peripheral and
central neuropathic pain in adults, adjunctive therapy in
adults with partial seizures with or without secondary
generalization, and treatment of GAD in adults [3]. The
absorption is rapid (peak plasma concentrations occur
within 1.5 h) after oral administration and exposure to
single (25–300 mg/day) or multiple dosages
(75–900 mg/day) is dose proportional and oral bioavail-
ability is high (C90 %) and independent of dose [1].
Pregabalin is a Biopharmaceutical Classification Sys-
tem (BCS) Class I compound (highly permeable and
highly soluble) [10]. Additionally, pregabalin does not
have a narrow therapeutic index and the formulations
were not modified release. Taking these in consideration,
the concept of biowaiver based on BCS should be con-
sidered as a surrogate for in vivo bioequivalence [5]. A
generic medicinal product is considered bioequivalent to a
reference medicinal product when the 90 % confidence
interval around the estimated ratio of geometric means
(GMR) of AUC and Cmax is between 0.80 and 1.25. As
per regulatory and scientific requirements, when a generic
medicinal product and a reference medicinal product are
compared, a single-dose crossover design is recom-
mended [5].
The treatment periods should be separated by a washout
period of at least 5 elimination half-lives in order to
guarantee that the drug concentrations are below the lower
limit of bioanalytical quantification (LOQ) in all subjects at
the beginning of each period [5].
In this study, the treatment periods were separated by a
washout period of 7 days to ensure that no carry-over ef-
fect is observed, corresponding to more than 10 times the
expected half-life of the measured moiety [5].
The means of the individual ratio of AUC(0–t) over
AUC(0–?) (AUC(0–t)/AUC(0–?)) were 97.64 and 97.69 %,
respectively, for the test drug product and reference drug
product. This implies that the blood sampling schedule was
defined adequately to characterize at least 80 % of the area
under the curve for both products [5].
Other authors conducted bioequivalence studies of pre-
gabalin with different washout periods and blood sampling
schedules [8, 9].
The intra-subject variability reflects the residual vari-
ability observed in the pharmacokinetic metrics after ac-
counting for possible differences between sequence,
period, and formulation effects as well as accounting for
between-subject variations. The intra-subject coefficient of
variation was 16.4 and 3.7 % for Cmax and AUC(0–t),
respectively.
All AEs reported for subjects included in the statistical
analysis were considered to have no impact on the phar-
macokinetic profiles of the drugs and the assessment of
bioequivalence. During the study, five severe AEs were
observed: four occurrences after test administration—fa-
tigue, headache and somnolence (two occurrences), and
one after reference administration—somnolence. None of
the AEs judged related to the investigational product were
considered unexpected, and, generally the drugs were
considered safe and well tolerated.
5 Conclusions
The results presented herein show that the criteria used to
assess bioequivalence between the test and reference for-























Fig. 2 Mean concentration
versus time curve—pregabalin
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geometric LS means and corresponding 90 % confidence
intervals for Cmax and AUC(0–t) were all within the ac-
ceptance range of 80.00–125.00 % as depicted in Table 2.
Therefore, it can be concluded that the test formulation
(pregabalin 300 mg hard capsules, West Pharma S.A.,
Portugal for Tecnimede S.A., Portugal) is bioequivalent to
the reference formulation (Lyrica 300 mg hard capsules,
Pfizer GmbH, Germany) following a 1 9 300 mg dose
under fasting conditions.
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